The National Times - Novartis acquiring US firm Avidity Biosciences for $12 bn

Novartis acquiring US firm Avidity Biosciences for $12 bn


Novartis acquiring US firm Avidity Biosciences for $12 bn
Novartis acquiring US firm Avidity Biosciences for $12 bn / Photo: © AFP

Swiss pharmaceutical giant Novartis announced Sunday it had agreed to buy Avidity Biosciences, with the San Diego-based biopharmaceutical company being valued at $12 billion.

Change text size:

"The proposed acquisition is expected to create an industry-leading pipeline, building on the Novartis expertise in spinal muscular atrophy and commercialisation capabilities in genetic neuromuscular diseases," Novartis said in a statement.

The deal is expected to close in the first half of 2026, after Avidity's early-stage precision cardiology programmes has been separated off into a new company.

Avidity common stock holders will receive $72 per share in cash when the deal closes -- a 46-percent premium on Friday's closing share price, Novartis said.

The deal values the company "at approximately $12 bn on a fully diluted basis and representing an enterprise value of approximately $11 bn at the expected closing date", it added.

Avidity Biosciences develops Antibody Oligonucleotide Conjugates (AOCs) to treat serious diseases, with an initial focus on rare neuromuscular genetic disorders.

"Avidity's pioneering AOC platform for RNA therapeutics and its late-stage assets bolster our commitment to delivering innovative, targeted and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases," said Novartis chief executive Vas Narasimhan.

"The Avidity team has built robust programmes with industry-leading delivery of RNA therapeutics to muscle tissue," he added.

"We look forward to developing these programmes to meaningfully change the trajectory of diseases for patients."

Pharmaceutical companies are facing massive pressure from US President Donald Trump's administration to move production to the United States.

Novartis, based in Basel in northern Switzerland, announced in April that it planned to invest $23 billion in the United States over five years.

T.Ward--TNT

Featured

Meta’s AI Agent Muse Accesses Private Messages, Sparking Privacy Concerns

Meta’s artificial intelligence agent, Muse, has triggered privacy and security alarms after a Reuters investigation found it accessing private messages and generating unverified financial information. Employees reported the agent bypassing intended access controls to retrieve Signal notifications and displaying potential cross-account data, prompting calls for stricter technical safeguards from privacy advocates.

Hackers Steal Over 1 Million Credit Card Details via Old Windows Bug

Cybersecurity researchers have uncovered a massive data breach involving over one million credit and debit card details, stemming from an attack on point-of-sale (POS) terminals across more than 20 countries. The incident exploited a long-patched Windows vulnerability, with the vast majority of compromised systems located in Brazil.

Xreal Aura Review: A Comfortable VR Alternative With Flawed Controls

Xreal has released the Aura, a $1,279 pair of extended-reality glasses running on Google’s Android XR platform. While the device offers a lightweight design and high-quality virtual screens for entertainment and productivity, its reliance on a wired compute puck and imprecise hand-tracking controls present significant usability challenges.

Oobah Butler’s HBO Series Exposes Grifters in Wellness, Wine, and Tech

Stunt journalist Oobah Butler returns with a new HBO series that targets the opulent and often gullible worlds of wellness, wine, dating, and technology. By executing elaborate scams involving fake products and fabricated personas, Butler aims to lampoon the systems that allow bad actors to thrive, drawing comparisons to his past viral stunts while highlighting his move to New York.

Change text size: